A detailed history of Forum Financial Management, LP transactions in Abb Vie Inc. stock. As of the latest transaction made, Forum Financial Management, LP holds 52,752 shares of ABBV stock, worth $8.77 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
52,752
Previous 53,082 0.62%
Holding current value
$8.77 Million
Previous $9.1 Million 14.42%
% of portfolio
0.2%
Previous 0.19%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$163.84 - $199.33 $54,067 - $65,778
-330 Reduced 0.62%
52,752 $10.4 Million
Q2 2024

Jul 30, 2024

SELL
$154.79 - $180.76 $1.51 Million - $1.77 Million
-9,773 Reduced 15.55%
53,082 $9.1 Million
Q1 2024

May 09, 2024

SELL
$159.82 - $182.1 $20,456 - $23,308
-128 Reduced 0.2%
62,855 $11.4 Million
Q4 2023

Feb 07, 2024

SELL
$137.6 - $154.97 $190,576 - $214,633
-1,385 Reduced 2.15%
62,983 $9.76 Million
Q3 2023

Nov 03, 2023

BUY
$133.59 - $154.65 $2,003 - $2,319
15 Added 0.02%
64,368 $9.59 Million
Q2 2023

Jul 26, 2023

BUY
$132.51 - $164.9 $708,133 - $881,225
5,344 Added 9.06%
64,353 $8.67 Million
Q1 2023

Apr 19, 2023

BUY
$144.61 - $166.54 $60,736 - $69,946
420 Added 0.72%
59,009 $9.4 Million
Q4 2022

Jan 24, 2023

SELL
$138.31 - $165.87 $71,921 - $86,252
-520 Reduced 0.88%
58,589 $0
Q3 2022

Nov 07, 2022

BUY
$134.21 - $153.93 $146,423 - $167,937
1,091 Added 1.88%
59,109 $7.93 Million
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $276,753 - $351,844
2,011 Added 3.59%
58,018 $8.89 Million
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $220,010 - $272,971
1,667 Added 3.07%
56,007 $9.08 Million
Q4 2021

Feb 18, 2022

BUY
$107.43 - $135.93 $5.84 Million - $7.39 Million
54,340 New
54,340 $7.36 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $294B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Forum Financial Management, LP Portfolio

Follow Forum Financial Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Forum Financial Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Forum Financial Management, LP with notifications on news.